What 7 Analyst Ratings Have To Say About Health Catalyst
Health Catalyst (NASDAQ:HCAT) has observed the following analyst ratings within the last quarter:
BTIG Maintains Buy on Health Catalyst, Lowers Price Target to $50
BTIG analyst David Larsen maintains Health Catalyst (NASDAQ:HCAT) with a Buy and lowers the price target from $60 to $50.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 454 stocks hit new 52-week lows.
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 198 companies made new 52-week lows.
Piper Sandler Maintains Overweight on Health Catalyst, Lowers Price Target to $38
Piper Sandler analyst Jessica Tassan maintains Health Catalyst (NASDAQ:HCAT) with a Overweight and lowers the price target from $66 to $38.
Raymond James Maintains Strong Buy on Health Catalyst, Lowers Price Target to $40
Raymond James analyst John Ransom maintains Health Catalyst (NASDAQ:HCAT) with a Strong Buy and lowers the price target from $70 to $40.
RBC Capital Maintains Outperform on Health Catalyst, Lowers Price Target to $35
RBC Capital analyst Sean Dodge maintains Health Catalyst (NASDAQ:HCAT) with a Outperform and lowers the price target from $66 to $35.
Recap: Health Catalyst Q4 Earnings
Health Catalyst (NASDAQ:HCAT) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:05 PM.
Here's what investors need to know about the announcement.
Temple University Health System Selects Health Catalyst’s Data Platform
Health Catalyst, Inc. ((", Health Catalyst, ", NASDAQ:HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced an engagement with Temple